The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.
New data on the impact of different treatment strategies on the neuro-development of young children living with HIV has been released, showing normal development in all areas apart from visual perception.
Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
New study provides insights into the factors that influence treatment adherence in Latin America and the Caribbean. Results show that individuals from lower resource settings often achieve higher levels of adherence, contrary to predictions.
Lancet study reveals for the first time who can benefit most from immediate antiretroviral treatment – enabling prioritisation in low-resourced settings. But who is left behind?
Immediate antiretroviral treatment (ART) for people with low CD4 counts in China reduces overall mortality by 63% – confirming trials in other countries that have shown the benefit of early treatment for improved health outcomes.
Agreement ushers in first single-dose, affordable HIV treatment for low- and middle-income countries.
A pilot that saw health workers adopt ‘patient-centred’ communication at an HIV clinic in rural Tanzania led to a three-fold increase in the number of people openly reporting treatment adherence problems.
UNITAID partners to bring newer and more effective HIV treatment options to countries where they are needed most.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.